ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an inve… Read more
ContraFect Corporation (CFRXQ) - Total Assets
Latest total assets as of September 2023: $9.12 Million USD
Based on the latest financial reports, ContraFect Corporation (CFRXQ) holds total assets worth $9.12 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ContraFect Corporation - Total Assets Trend (2016–2022)
This chart illustrates how ContraFect Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ContraFect Corporation - Asset Composition Analysis
Current Asset Composition (September 2022)
ContraFect Corporation's total assets of $9.12 Million consist of 85.6% current assets and 14.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.1% |
| Accounts Receivable | $2.60 Million | 12.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2022)
This chart illustrates how ContraFect Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ContraFect Corporation's current assets represent 85.6% of total assets in 2022, a decrease from 96.2% in 2016.
- Cash Position: Cash and equivalents constituted 43.1% of total assets in 2022, up from 10.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.6% of total assets.
ContraFect Corporation Competitors by Total Assets
Key competitors of ContraFect Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ContraFect Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ContraFect Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ContraFect Corporation is currently not profitable relative to its asset base.
ContraFect Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 0.84 | 7.48 |
| Quick Ratio | 0.53 | 0.84 | 7.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.80 Million | $ -3.73 Million | $ 64.00 Million |
ContraFect Corporation - Advanced Valuation Insights
This section examines the relationship between ContraFect Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -69.0% |
| Total Assets | $20.68 Million |
| Market Capitalization | $107.00 USD |
Valuation Analysis
Below Book Valuation: The market values ContraFect Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ContraFect Corporation's assets decreased by 69.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ContraFect Corporation (2016–2022)
The table below shows the annual total assets of ContraFect Corporation from 2016 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-09-30 | $20.68 Million | -69.03% |
| 2021-09-30 | $66.76 Million | +30.61% |
| 2020-09-30 | $51.12 Million | +46.01% |
| 2019-09-30 | $35.01 Million | +6.50% |
| 2018-09-30 | $32.87 Million | -34.50% |
| 2017-09-30 | $50.19 Million | +33.40% |
| 2016-09-30 | $37.62 Million | -- |